16 results
8-K
EX-10.1
DRMA
Dermata Therapeutics Inc
24 May 23
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
5:13pm
of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension
424B4
DRMA
Dermata Therapeutics Inc
13 May 22
Prospectus supplement with pricing info
5:06pm
payable by us that result from such litigation;
costs associated with any product recall that could occur;
costs of operating as a public company … a product recall.
The regulations, policies or guidance of the FDA and other applicable government agencies may change and new or additional statutes
8-K
EX-10.1
DRMA
Dermata Therapeutics Inc
25 Apr 22
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
4:45pm
and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders
10-K
llea4 y8yljauxwbynbf
28 Mar 22
Annual report
8:33am
DRS
1tdt x8w6as8
11 Jan 22
Draft registration statement
12:00am
424B4
liytfid92i 6f
16 Aug 21
Prospectus supplement with pricing info
4:54pm
S-1
rx7ox
10 Jun 21
IPO registration
5:11pm
DRS/A
kq01cmb
7 May 21
Draft registration statement (amended)
12:00am
DRS
6fxty jq4yz
2 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next